{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:05:26Z","timestamp":1784268326484,"version":"3.55.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatic arterial infusion chemotherapy (HAIC) is a valuable option in patients with liver-dominant metastatic colorectal cancer (mCRC) but remains underutilized due to limited data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of mCRC patients treated with HAIC in an expert center between 2010 and 2024. Patients were grouped according to treatment setting: intensification (INT; 1st\/2nd line) and salvage (SALV; \u22653rd line).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 213 patients, 99 received INT-HAIC and 114 SALV-HAIC. SALV patients had worse baseline features, including more Eastern Cooperative Oncology Group performance status (ECOG PS \u2265 2; 16% vs 4%), RAS mutation (55% vs 45%), extra-hepatic disease (45% vs 23%), liver burden &amp;gt;50% (65% vs 40%), and prior intravenous (IV) oxaliplatin progression (41% vs 16%). Oxaliplatin was the main agent used (81% INT, 78% SALV). Objective response and disease control rate were 51%\/77% (INT) and 32%\/60% (SALV). Median progression-free survival (PFS), hepatic PFS, and overall survival were 7.6, 9, and 23\u2009months (INT) and 3.7, 5.7, and 12\u2009months (SALV). Prior IV oxaliplatin progression was associated with poorer outcomes of oxaliplatin-HAIC in the INT setting. Radical liver treatment followed HAIC in 28% (INT) and 7% (SALV). Grade 3\u20134 adverse events occurred in 42.7% and catheter complications in 26.7%. Concomitant antiangiogenic therapy was associated with a higher rate of catheter-related complications (44% vs 22%) and remained associated after adjustment for clinical covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HAIC demonstrates promising efficacy and manageable toxicity in liver-dominant mCRC when delivered in expert multidisciplinary centers, although careful patient selection and caution with concomitant antiangiogenic therapy are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag214","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:44:00Z","timestamp":1780487040000},"source":"Crossref","is-referenced-by-count":0,"title":["Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: real-world outcomes of intensification and salvage strategies"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-5108","authenticated-orcid":false,"given":"Annalice","family":"Gandini","sequence":"first","affiliation":[{"name":"Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris, 75015,","place":["France"]},{"name":"SIRIC CARPEM Comprehensive Cancer Center, Paris-Cit\u00e9 University , Paris, 75006,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Lipsich","sequence":"additional","affiliation":[{"name":"Department of Vascular and Oncological Interventional Radiology, H\u00f4pital Europ\u00e9en Georges, Pompidou, Paris, 75015,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm, Centre de Recherche des Cordeliers , F-75006 Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Netter-Coti","sequence":"additional","affiliation":[{"name":"Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris, 75015,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Widad","family":"Lahlou","sequence":"additional","affiliation":[{"name":"Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris, 75015,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-6000","authenticated-orcid":false,"given":"Celine","family":"Lepere","sequence":"additional","affiliation":[{"name":"Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris, 75015,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Guerra","sequence":"additional","affiliation":[{"name":"SIRIC CARPEM Comprehensive Cancer Center, Paris-Cit\u00e9 University , Paris, 75006,","place":["France"]},{"name":"Department of Vascular and Oncological Interventional Radiology, H\u00f4pital Europ\u00e9en Georges, Pompidou, Paris, 75015,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Pellerin","sequence":"additional","affiliation":[{"name":"SIRIC CARPEM Comprehensive Cancer Center, Paris-Cit\u00e9 University , Paris, 75006,","place":["France"]},{"name":"Department of Vascular and Oncological Interventional Radiology, H\u00f4pital Europ\u00e9en Georges, Pompidou, Paris, 75015,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[{"name":"Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris, 75015,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm, Centre de Recherche des Cordeliers, F-75006 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Boeken","sequence":"additional","affiliation":[{"name":"SIRIC CARPEM Comprehensive Cancer Center, Paris-Cit\u00e9 University , Paris, 75006,","place":["France"]},{"name":"Department of Vascular and Oncological Interventional Radiology, H\u00f4pital Europ\u00e9en Georges, Pompidou, Paris, 75015,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2369-7341","authenticated-orcid":false,"given":"Claire","family":"Gallois","sequence":"additional","affiliation":[{"name":"Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris, 75015,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm, Centre de Recherche des Cordeliers , F-75006 Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2026071701221374600_oyag214-B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026071701221374600_oyag214-B2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1470-2045(21)00199-6","article-title":"Colorectal cancer incidence, mortality, and stage distribution in european countries in the colorectal cancer screening era: an international population-based study","volume":"22","author":"Cardoso","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026071701221374600_oyag214-B3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clcc.2012.06.004","article-title":"Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer","volume":"11","author":"Khattak","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"2026071701221374600_oyag214-B4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"2026071701221374600_oyag214-B5","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis","year":"1954","journal-title":"Am J Pathol"},{"key":"2026071701221374600_oyag214-B6","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1016\/j.ejca.2011.06.037","article-title":"Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer","volume":"47","author":"Bouchahda","year":"2011","journal-title":"Eur J Cancer"},{"key":"2026071701221374600_oyag214-B7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"L\u00e9vi","year":"2016","journal-title":"Ann Oncol"},{"key":"2026071701221374600_oyag214-B8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1245\/s10434-025-18570-5","article-title":"Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy: exploratory findings from a prematurely closed multicenter randomized phase II study: SULTAN UCGI 30\/PRODIGE 53 (NCT03164655)","volume":"33","author":"Boil\u00e8ve","year":"2026","journal-title":"Ann Surg Oncol"},{"key":"2026071701221374600_oyag214-B9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12885-020-6571-7","article-title":"Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy\u2013a randomized phase II study\u2014SULTAN UCGI 30\/PRODIGE 53 (NCT03164655)- study protocol","volume":"20","author":"Boil\u00e8ve","year":"2020","journal-title":"BMC Cancer"},{"key":"2026071701221374600_oyag214-B10","doi-asserted-by":"publisher","first-page":"113400","DOI":"10.1016\/j.ejca.2023.113400","article-title":"Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: a multicenter phase II trial","volume":"195","author":"Malka","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026071701221374600_oyag214-B11","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1200\/JCO.2023.41.16_suppl.3515","article-title":"Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a multicenter randomized phase II trial (PRODIGE 43 - PACHA-01)","volume":"41","author":"Gelli","year":"2023","journal-title":"JCO"},{"key":"2026071701221374600_oyag214-B12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.dld.2021.12.012","article-title":"Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +\/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49","volume":"54","author":"Pernot","year":"2022","journal-title":"Dig Liver Dis"},{"key":"2026071701221374600_oyag214-B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2020.07.022","article-title":"Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases","volume":"138","author":"Boil\u00e8ve","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026071701221374600_oyag214-B14","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"Kemeny","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026071701221374600_oyag214-B15","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2026071701221374600_oyag214-B16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1245\/s10434-013-3275-0","article-title":"Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab","volume":"21","author":"Cercek","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2026071701221374600_oyag214-B17","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1245\/s10434-024-15729-4","article-title":"A modified floxuridine reduced-dose protocol for patients with unresectable colorectal liver metastases treated with hepatic arterial infusion","volume":"31","author":"Schwantes","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026071701221374600_oyag214-B18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/jso.24399","article-title":"Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies","volume":"114","author":"Cercek","year":"2016","journal-title":"J Surg Oncol"},{"key":"2026071701221374600_oyag214-B19","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1200\/JCO.2001.19.10.2687","article-title":"Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer","volume":"19","author":"Kemeny","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag214\/68475743\/oyag214.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag214\/68475743\/oyag214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag214\/68475743\/oyag214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:22:19Z","timestamp":1784265739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag214\/8702461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag214","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,4]]},"article-number":"oyag214"}}